下调转化生长因子β激活激酶1抑制胰腺神经内分泌肿瘤转移和侵袭被引量：1

Downregulation of transforming growth factorβ-activated kinase 1 inhibits the metastasis and invasion of pancreatic neuroendocrine neoplasms

在线阅读下载PDF

导出

摘要目的探究转化生长因子β激活激酶1(TAK1)在胰腺神经内分泌肿瘤(p-NENs)进展中的作用与影响。方法采用实时定量荧光聚合酶链反应(qRT-PCR)和蛋白印迹法(Western blotting)检测p-NENs细胞株(BON-1)、人正常胰腺导管上皮细胞系(hTERT-HPNE)和人胰腺导管腺癌细胞系(CFPAC-1)中TAK1表达情况。采用靶向TAK1的短发夹RNA(shRNA),以慢病毒为载体对BON-1进行基因敲降。通过四甲基偶氮唑蓝(MTT)法和EdU实验观察细胞增殖活力,Transwell实验观察细胞侵袭与迁移能力变化,Western blotting检测上皮间质转化(epithelial-mesenchymal transition,EMT)相关标志性蛋白表达。结果BON-1中TAK1 mRNA和蛋白质水平的表达相较于hTERT-HPNE和CFPAC-1明显升高(P<0.05),抑制BON-1中TAK1的表达后,细胞的增殖能力无明显变化,但细胞的迁移和侵袭能力明显减弱(P<0.05)。与对照组相比,敲降组的EMT相关蛋白中,上皮细胞标志性蛋白E-cadherin表达升高,间质细胞标志性蛋白Vimentin和N-cadherin表达明显降低(P<0.05)。结论在BON-1中,抑制TAK1的表达能够抑制肿瘤细胞的EMT过程,降低细胞的迁移和侵袭能力,从而抑制p-NENs的进展。 Objective To investigate the function of transforming growth factorβ-activated kinase 1(TAK1)on the progression of pancreatic neuroendocrine neoplasms(p-NENs).Methods Quantitative real time fluorescence polymerase chain reaction(qRT-PCR)and Western blotting were performed to detect TAK1 expression of p-NENs cells(BON-1),human normal epithelial cells of pancreas(hTERT-HPNE)and human pancreatic cancer cells(CFPAC-1).Short hairpin RNA(shRNA)was transfected on BON-1 to downregulate the expression of TAK1,and then cell proliferation was detected by MTT and EdU assay.The migratory and invasive ability of cells were detected by transwell assay.Western blotting was used to detect the expression of epithelial-mesenchymal transition(EMT)related protein.Results The expressions of TAK1 mRNA and protein in BON-1 were significantly increased compared with hTERT-HPNE and CFPAC-1(P<0.05).After inhibiting the expression of TAK1 in BON-1,it had no obvious effect on the proliferation of cells,but the migratory and invasive abilities of cells were significantly repressed compared with the control group(P<0.05).Moreover,in the knockdown group,the expression of epithelial marker E-cadherin was increased,while mesenchymal marker Vimentin and N-cadherin were significantly decreased(P<0.05).Conclusion The silence of TAK1 could significantly attenuate the process of EMT,and inhibit the migration and invasion of BON-1.Therefore,targeting against TAK1 is likely as a potential therapeutic strategy for the treatment of p-NENs.

作者杨晓玉柏建安孙诚汤琪云 YANG Xiaoyu;BAI Jian’an;SUN Cheng;TANG Qiyun(Department of Gastroenterology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029;Department of Geriatric Medicine,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029;Jiangsu Key Laboratory of Neuroregeneration,Nantong University,China)

机构地区南京医科大学第一附属医院消化科南京医科大学第一附属医院老年消化科南通大学神经再生重点实验室

出处《胃肠病学和肝病学杂志》 CAS 2020年第4期406-410,共5页 Chinese Journal of Gastroenterology and Hepatology

基金江苏省“333”工程项目(BRA2017535)。

关键词转化生长因子β激活激酶1 侵袭迁移胰腺神经内分泌肿瘤上皮间质转化 Transforming growth factorβ-activated kinase 1 Invasion Migration Pancreatic neuroendocrine neoplasms Epithelial-mesenchymal transition

分类号 R735 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1陈洛海,陈洁.胰腺神经内分泌肿瘤的药物治疗及其进展[J].中国实用外科杂志,2019,0(9):929-934. 被引量：7
2郑佳彬,李勇.胃肠胰神经内分泌肿瘤的诊治进展[J].广东医学,2015,36(3):481-483. 被引量：6

二级参考文献27

1YAO J C, HASSAN M, PHAN A, et al. One hundred years after "carcinoid" : Epidemiology of and prognostic factors for neuroen- docrine tumors in 35, 825 cases in the United States [ J ]. J Clin Oncol, 2008, 26 ( 18 ) : 3063 - 3072.
2SALAMA A, BADAWY O, MOKHTAR N. Ki -67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10 - year experience [ J]. Cancer Res Clin Oncol, 2014, 140 (4) : 653 -661.
3FOLTYN W, ZAJECKI W, MAREK B, et al. The value of the Ki - 67 proliferation marker as a prognostic factor in gastroenteropanere- atie neuroendoerine tumours [ J ]. Endokrynol Pol, 2012, 63 ( 5 ) : 362 - 366.
4MCCALL C M, SHI C, CORNISH T C, et al. Grading of well - differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotierate [J]. Am J Surg Pathol, 2013, 37( 11 ) : 1671 -1677.
5KALTSAS G A, BESSER G M, GROSSMAN A B. The diagnosis and medical management of advanced neuroendocrine tumors [ J ]. Endocr Rev, 2004, 25(3): 458-511.
6HAKIM F A, ALEXANDER J A, HUPRICH J E, et al. CT - en- terography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at Mayo Clinic Rochester[ J ]. Dig Dis Sci, 2011, 56(10) : 2914 -2919.
7ADAMS S, BAUM R, RINK T, et al. Limited value of fluorine - 18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors[J]. Cur J Nucl Med, 1998, 25(1) : 79 -83.
8NIKOLAOU A, THOMAS D, KAMPANELLOU C, et al. The val- ue of 11 C - 5 - hydroxy - tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience fmmone center[J]. J Endocrinol Invest, 2010, 33(11): 794-799.
9GABRIEL M, DECRISTOFORO C, KENDLER D, et al. 68Ga - DOTA - Tyr3 - octreotide PET in neuroendoerine tumors : Compar- ison with somatostatin receptor scintigraphy and CT [ J ]. Nuel Med, 2007, 48(4) : 508 -518.
10BAJETrA E, FERRARI L, MARTINETrI A, et al. Chromogra- nin A, neuron specific enolase, carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendo- erine tumors[J]. Cancer, 1999, 86(5): 858-865.